Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Total Current Liabilities
All obligations due within one year.
Maze Therapeutics, Inc.NASDAQ: MAZE
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 14.1% from a year ago
Total current liabilities stood at $21.24M at the end of Q1 FY2026, up 14.1% from a year earlier and down 5.9% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Total current liabilities amounted to 5.1% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +14.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 22.56M USD
- Year-over-year change
- +9.1%
- 3-year CAGR
- +2.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.56M | +9.1% |
| FY2024 | 2024-12-31 | 20.67M | +26.7% |
| FY2023 | 2023-12-31 | 16.32M | -21.5% |
| FY2022 | 2022-12-31 | 20.78M | — |
Total Current Liabilities vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +14.1% is the 6th highest of 8, against a peer median of +23.2%.
- Total current liabilities amounts to 5.1% of total assets for MAZE, versus a peer median of 21.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $771.07M USD | +22.8% | +33.6% | 23.7% | |
| Sep 2026 | $210.91M USD | +56.1% | +4.0% | 24.9% | |
| Mar 2026 | $109.57M USD | +44.5% | +10.5% | 21.7% | |
SEPNSepterna, Inc. | Sep 2026 | $104.86M USD | +39.3% | +150.3% | 16.9% |
| Dec 2025 | €77.35M EUR | -35.9% | +36.1% | 31.1% | |
| Mar 2026 | $21.24M USD | +14.1% | +2.8% | 5.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $15.83M USD | -33.3% | +50.9% | 4.0% |
| Mar 2026 | $5.75M USD | +23.2% | +33.3% | 10.8% | |
| Peer median (excluding MAZE) | — | +23.2% | +33.6% | 21.7% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.